title: Antiangiogenic treatment in age-related macular degeneration in patients with a history of cerebrovascular risk.
authors: L
authors: L
authors: García-López
authors: R
authors: R
authors: Coloma Peral
authors: M T
authors: MT
authors: Criado Illana
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage / Q000627:therapeutic use; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D001991:Bronchitis / Q000150:complications; D004198:Disease Susceptibility; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000150:complications; D020766:Intracranial Embolism / Q000139:chemically induced / Q000209:etiology*; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D000069579:Ranibizumab; D012306:Risk; D019851:Thrombophilia / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D017984:Enoxaparin; D000074:Acenocoumarol; D000069579:Ranibizumab